Scott Gottlieb, MD 🇺🇸· @ScottGottliebMD · X·· 2 小时前精选AI 评分62
AI 导读
前FDA局长Scott Gottlieb就FDA在 new leadership 下推动罕见病审批改革发表评论，称这是提升FDA罕见病治疗开发流程协调性的有意义一步，将有助于加速新政策制定。他同时链接了彭博社关于FDA拟改革罕见病审批的报道。
推荐理由
前FDA局长对FDA罕见病审批改革举措的解读，可了解该机构在罕见病治疗开发流程上的政策走向。
正文
This is a meaningful step to bring better coordination around FDA initiatives to make the process for developing treatments for rare diseases more efficient. Will help accelerate new policy development.
https://www.bloomberg.com/news/articles/2026-10-14/fda-aims-to-overhaul-rare-disease-approvals-under-new-leadership
来源：Scott Gottlieb, MD 🇺🇸 · x.com